Format

Send to

Choose Destination
J Med Vasc. 2020 Feb;45(1):28-40. doi: 10.1016/j.jdmv.2019.12.004. Epub 2020 Jan 8.

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC).

Author information

1
Eurocord, Équipe 3 EA3518, hôpital Saint-Louis, Université de Paris, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: hanadi.rafii-elayoubi@aphp.fr.
2
Inserm UMRS_1166, Department of Haematology, hôpital Pitié-Salpêtrière, Université de Paris, Sorbonne Paris-Cité, AP-HP, Paris, France.
3
Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France.
4
Hôpital Saint-Antoine, AP-HP, Paris, France.
5
Montpellier school of Medicine, Saint-Eloi University Hospital, Montpellier, France.
6
Hôpital Rangueil, CHU de Toulouse, Toulouse, France.
7
Hôpital Saint-Louis, AP-HP, Paris, France.
8
CHU de Nantes, Nantes, France.
9
Saint-Joseph Hospital, Paris, France.
10
CHU de Nîmes, Nîmes, France.
11
CHU Saint-Étienne, Saint-Étienne, France.
12
Hôpital Européen Georges-Pompidou, AP-HP, Paris, France.
13
Internal Medicine (UF04), Équipe 3 EA 3518, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, AP-HP, Sorbonne Paris-Cité, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada.

Abstract

Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer progression. VTE management and prophylaxis are critical in cancer patients, but effective therapy can be challenging because these patients are at higher risk of VTE recurrence and bleeding under anticoagulant treatment. Numerous published studies report inconsistent implementation of existing evidence-based clinical practice guidelines (CPG), including underutilization of thromboprophylaxis, and wide variability in clinical practice patterns across different countries and various practitioners. This review aims to summarize the 2019 ITAC-CME evidence-based CPGs for treatment and prophylaxis of cancer-related VTE, which include recommendations on the use of direct oral anticoagulants specifically in cancer patients. The guidelines underscore the gravity of developing VTE in cancer and recommend the best approaches for treating and preventing cancer-associated VTE, while minimizing unnecessary or over-treatment. Greater adherence to the 2019 ITAC guidelines could substantially decrease the burden of VTE and improve survival of cancer patients.

KEYWORDS:

Cancer; Catheter-related thrombosis; Clinical practice guidelines; LMWH; Oral anticoagulants; Venous thromboembolism

PMID:
32057323
DOI:
10.1016/j.jdmv.2019.12.004

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center